Ask AI

Advances in Oral Targeted Therapies for HR+/HER2- Breast Cancer: Best Practices for Oncology Pharmacists

Enhance your ability to integrate oral targeted therapies for HR-positive/HER2-negative breast cancer into clinical practice to individualize patient care and improve outcomes through certified downloadable slides, certified text modules, an expert-authored ClinicalThought commentary, and an audio podcast.

Share

Program Content

Events

  • Live Event
    Advances in Oral Targeted Therapies for HR+/HER2- Breast Cancer: Best Practices for Oncology Pharmacists
    Congratulations: You achieved a completion on 04/09/2022

    You can enroll in the following live event(s) on this topic.

Activities

HRpos HER2neg Breast Cancer
Advances in Oral Targeted Therapies for HR+/HER2- Breast Cancer: Best Practices for Oncology Pharmacists
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 20, 2026

Provided by

ProCE Banner

Provided by ProCE, LLC.

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca